Background/Aim
Introduction
Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically important swine diseases worldwide. In the United States, direct economic loss due to PRRS is estimated to exceed $600 million per year [1, 2] . PRRS virus (PRRSV) is an arterivirus in the Arteriviridae family with a single-stranded positive sense RNA genome of~15 Kb encoding 10 open reading frames [3] [4] [5] . Rapidly and continuously increasing genetic diversity among PRRSV isolates [3, 6, 7] and emergence of highly pathogenic variants in different geographical regions [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] present a tremendous challenge to the control of PRRSV using conventional vaccines.
Both inactivated and live attenuated virus vaccines are used to aid PRRS control in swine herds, but the efficacy and/or safety of current licensed vaccines are not satisfactory [20] [21] [22] . Inactivated PRRSV vaccines induce weak neutralizing antibody responses even against homologous isolates and weaker to no response against heterologous isolates [21, 23, 24] . Live attenuated PRRSV vaccines contribute to clinical protection by unknown mechanisms without preventing infection, but a high probability of reversion to virulence is a major safety concern [9, 25, 26] . To better control PRRSV infections worldwide, it is crucial to develop a safer and more efficacious vaccine that confers protective immunity against diverse PRRSV isolates.
There have been numerous attempts to determine if neutralizing antibody provides protective immunity against PRRSV [27] [28] [29] [30] [31] [32] [33] . Passive transfer of hyperimmune serum containing high titer neutralizing antibody against PRRSV controlled viremia in pigs challenged with homologous PRRSV, but was not able to prevent viral replication in tissues [31, 34] . In addition, neutralizing antibodies did not provide protection against heterologous challenge [32] . Several studies have found that immunization with live attenuated and killed PRRSV vaccines reduced clinical disease and/or viremia in pigs after PRRSV challenge, before the appearance of neutralizing antibody responses [29, 30, 33, [35] [36] [37] . These observations, as well as the co-existence of infectious PRRSV and low titer neutralizing antibodies in the blood of infected pigs [27, 28, 38, 39] , lead to the conclusion that neutralizing antibodies alone are not potent enough to control PRRSV infection in pigs recovered from natural infections or vaccinated pigs.
Other mechanisms such as cell-mediated immunity (CMI) may contribute to control of PRRSV. Such correlates of protective immunity have not been clearly defined. Therefore, systematic approaches are needed to evaluate if CMI is more important than humoral immunity in the control of infections with diverse PRRSV isolates. A crucial step for defining the relative advantage of CMI versus humoral immunity in PRRSV-infected pigs is to determine if CMI has the potential to overcome the challenge of antigenic variation between diverse isolates. In this study, cross reactive T-lymphocyte responses against genetically and antigenically divergent PRRSV isolates were demonstrated in two pig groups of different ages using an interferon (IFN)-gamma ELISpot assay. Peptides containing T-lymphocyte epitopes were mapped to PRRSV proteins with several occurring in the M protein, one of which was recognized by Tlymphocytes from all three gilts used for mapping. These observations should help define both cytotoxic and helper T-lymphocyte epitopes that may be used for development of improved and novel PRRSV vaccines that provide protection against genetically and antigenically diverse isolates.
Methods

Sequencing and phylogenetic analysis of PRRSV open reading frame 5 (ORF5)
The extraction of viral RNA from three PRRSV isolates (O-1, 3606, 14003), reverse transcription (RT) and polymerase chain reaction (PCR) amplification of the gene encoded by ORF5, and DNA sequencing were carried out as previously described [40] . Briefly, total RNA was extracted from each of virus culture supernatants using the viral RNA isolation kit from Life Technologies (Grand Island, NY, USA). The RT reaction mixture consisted of 13 μL total RNA, 1 μL of 10 mM random primer (New England Biolabs, Ipswich, MA, USA), 1 μL (50 U) of reverse transcriptase (Promega, Madison, WI, USA), 4 μL of 5× buffer (Promega), and 1 μL of 10 mM dNTPs (Life Technologies). Reverse transcription was conducted at 37°C for 30 minutes using a thermal cycler (Applied Biosystems model 2720, Life Technologies) to produce full-length cDNA. ORF5 sequences of three PRRSV strains were then PCR amplified from cDNA using 1 μL of each of 100 μM concentration primers (VR-F: TTAGCCTGTCTTTTTGC CATTCT and VR-R: TGT GGAGCCGTGCTATCAT for type-2 PRRSVs [O-1, 3606]; LV-F: ATTGCTTGTTTGTTCGCCA, LV-R: AAGGCTAGCACGAGCTTTTGT for type-1 PRRSV [SD14003]) and 9 μL of PRRSV cDNAs in a PCR mixture which contained 0.4 μL of 5U/μL high fidelity DNA polymerase (Life Technologies), 5 μL of 10X buffer, 5 μL of 50 mM MgSO 4 (Life Technologies), 5 μL of 10 mM dNTPs, and 23.6 μL of distilled water. PCR cycles were 94°C for 5 minutes, followed by 35 cycles of 94°C for 1 minute, 53°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 10 minutes. The PCR products were purified using the QIAquick The titer of PRRSV in each cell culture supernatant was determined using a microtitration infectivity assay and the median tissue culture infective dose (TCID 50 ) calculated according to the method of Reed and Muench [48] . Briefly, confluent monolayers of MARC-145 cells prepared in 96-well plates (Corning) were inoculated with 10-fold serial dilutions of PRRSV prepared in EMEM with 10% FBS. The development of CPE in the cells was monitored daily for seven days and the results were used to calculate TCID 50 /mL.
PRRSV-infected pigs
Three 12-month-old gilts (numbered 1-3) from the same dam were determined to be negative for porcine circovirus, porcine epidemic diarrhea virus, and PRRSV by realtime PCR and and 12 (35.5 Ct) dpi, and negative viremia (!37.0 Ct) after 12 dpi. Gilt-3 had weak positive viremia (36.0 Ct) at 4 dpi only and negative viremia at later dpi. Gilt-1 had no detectable viremia (!37.0 Ct) at all tested dpi although appearance of PRRSV-specific antibodies after intranasal inoculation of PRRSV SD23983 clearly demonstrates the infection. These gilts were the source of peripheral blood mononuclear cells (PBMC) collected at 30-33, 44, 58 and 72 days post-infection (dpi) for in vitro stimulation with PRRSV or peptides. Gilt 1 was artificially inseminated with semen of a PRRSV-negative boar and then infected with the virus at approximately 98 days of gestation. Nine piglets (numbered P13-P21) were born to gilt 1 at approximately 117 days of gestation and confirmed PRRSV-infected at birth prior to ingestion of colostrum, indicating in utero infection. PBMC were also collected from the nine piglets at 14 days of age (33 dpi). The animal use protocols for these animal studies were approved by the Institutional Animal Care and Use Committees at Washington State University. Proper sedation and anesthesia were used to minimize potential pain in sampling procedure from the gilts used in this study.
MHC class I and II typing of gilts and piglets
Gilts 1-3 and the nine piglets used in this study were genotyped for three swine leukocyte antigen (SLA) class I genes (SLA-1, -2, -3) and three class II genes (DRB1, DQB1, DQA) using the low resolution PCR-SSP (polymerase chain reaction with sequence-specific primers) typing panels as previously described [49, 50] . Low resolution SLA class I and class II haplotypes were deduced based on published (15713212, 16305679, 18760302, 19317739) and unpublished (http://www.jimmunol.org/cgi/content/meetingabstract/186/1_MeetingAbstracts/170.1) haplotypes identified in outbred commercial pigs.
Preparation of peripheral blood mononuclear cells and storage
Swine PBMC from fresh venous blood collected in 5 mM EDTA (final concentration) were isolated by centrifugation on a discontinuous gradient using Lymphoprep™ (STEMCELL™ Technologies, Vancouver, Canada) as previously described [51] . Briefly, blood with 5 mM EDTA was diluted two-fold in 10mM phosphate-buffered saline (PBS, pH 7.4) containing 20% anticoagulant citrate dextrose (ACD) and 2% FBS. Thirty-five milliliters of the diluted blood was added to a SepMate™-50 tube (STEMCELL Technologies) containing 15 mL of Lymphoprep™ and the tubes were centrifuged at 1,100 × g for 10 minutes. The buffy coat cells within the supernatant were collected and rinsed with PBS containing 20% ACD and 2% FBS until platelets were removed. Isolated PBMCs were counted, resuspended in a freezing medium containing 10% dimethyl sulfoxide (J.T. Baker, Center Valley, PA, USA) and 90% FBS, and stored in liquid nitrogen until use.
IFN-gamma enzyme-linked immunospot (ELISpot) assay
The IFN-gamma ELISpot assay used to define PRRSV-specific T-lymphocyte responses was performed using a commercial product (Mabtech, Cincinnati, OH, USA) as per manufacturer's instructions. In brief, ELISpot plates were coated with anti-IFN-gamma antibody (1 ng/well) diluted in sterile 10 mM PBS (pH 7.4) by incubating at 4°C overnight. Wells were washed five times with PBS and blocked/equilibrated with RPMI-1640 media (Life Technology, Grand Island, NY, USA) containing 10% FBS for two hours at ambient temperature. PBMC (10 5 to 10 6 cells) in 100 μL of RPMI-1640 media supplemented with 10% FBS were added to each well of ELISpot plates. Each PRRSV antigen (e.g. live PRRSV at 10 5 TCID 50 , inactivated PRRSV or peptides at one to four μM) or mitogen (PHA 0.5 μg) suspended in 100 μL of RPMI-1640 media was then added to each well. The plates were incubated at 37°C for approximately 20 hours in a water-jacketed incubator conditioned with 5% CO 2 . To detect the spots associated with IFN-gamma secretion from antigen-specific T-lymphocytes, the plates were washed five times with PBS and biotinylated anti-IFN-gamma antibody (0.05 μg/100 μL/well) was added. Following two hours of incubation at ambient temperature, the plates were washed and then incubated with 100 μL of 1000-fold diluted streptoavidin-HRP (Mabtech) per well for one hour at ambient temperature. The plates were again washed five times with PBS and, following the addition of 100 μL of substrate solution, color spots were developed for approximately 90 seconds. The colorimetric reaction was stopped by rinsing with distilled water, and the plates were dried in the dark until spot forming units (SFU) were analyzed by an ELISpot reader (Autoimmun Diagnostika GmbH, Strasberg, Germany). The mean SFU/10 6 PBMC and standard error (SE) were calculated for the three non-stimulated negative control wells. For the test wells (two per test unless otherwise indicated), the mean was calculated and the negative control mean subtracted to determine mean antigen-specific SFU (representative data in S1 Fig) .
Those tests with a mean antigen-specific SFU higher than the mean SFU in non-stimulated wells plus five times the SE (!99% confidence interval) were considered significant positive results.
T-lymphocyte epitope mapping
Peptides consisting of 20 amino acids with 11 amino acid overlaps were synthesized for all structural and nonstructural proteins of PRRSV SD23983 by a commercial manufacturer (Mimotope Pty Ltd., Clayton, Australia). These synthetic peptides were used in ELISpot assay to define the location of epitopes recognized by T-lymphocytes from PRRSV-infected gilts.The initial round of screening was with pools containing 33-54 peptides per pool (~1 μM of each peptide) and those that were positive were tested in the second round with smaller pools containing two to four peptides (4 μM of each). The third round of screening tested each peptide individually from positive pools identified in the second round (4 μM of each). All individual peptides inducing a significant T-lymphocyte response in the third round were retested with four replicates of each peptide.
Fluorescent focusing neutralization (FFN) assay
The PRRSV neutralizing antibody response in serum was measured by FFN assay as previously described [52] . Briefly, two-fold serial dilutions (1:4 to 1:512) of heat-inactivated serum samples were prepared in 96-well plates using Minimum Essential Medium (MEM, GIBCO 1 brand; Life Technology, Grand Island, NY, USA) supplemented with 10% FBS. An equal volume (50 μL) of PRRSV (VR-2332 or SD23983 strain) at a concentration of 2 × 10 3 FFU 50 per ml was added to each sample, incubated for one hour at 37°C, and transferred to a 96-well plate containing confluent MARC-145 cells. After 24 hours, the plates were washed, fixed in ice-cold 80% acetone (Fisherbrand
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; Fisher Scientific, Hanover Park, IL, USA), and stained with fluorescein isothiocyanate-conjugated anti-PRRSV nucleocapsid monoclonal antibody SDOW17 (Rural Technologies, Brookings, SD, USA) diluted 1:100 in PBS. The neutralizing activity of each serum (i.e., FFN titer) was reported as the reciprocal of the highest dilution that caused a 90% or greater reduction in the number of fluorescent foci.
Results
T-lymphocytes from pigs infected with type-2 PRRSV SD23983 recognized highly diverse type-1 and -2 PRRSV isolates
To define T-lymphocyte responses reacting against diverse PRRSV isolates, PBMCs collected from three one-year-old gilts at 44 and 72 days following infection with type-2 PRRSV SD23983 were evaluated by IFN-gamma ELISpot assay using 12 diverse PRRSV isolates as antigen. Gilts 1 and 3 had identical MHC haplotypes (Class I = Lr-32.0/35.0, Class II = Lr-0.1/0.12) and had broadly cross-reactive PRRSV-specific T-lymphocyte responses at 44 dpi, recognizing 11 of 12 heterologous PRRSV isolates significantly high (>5 SE) (Table 1) . Notably, one of the recognized isolates included the type-1 PRRSV Lelystad , which has more than 40% difference in GP5 and complete ORF sequences from major type-2 PRRSV isolates, including the type-2 PRRSV SD2398 inoculum virus as well as PRRSV VR2332 (Fig 1) . Gilt 2 had a different MHC haplotype (Class I = Lr-4.0/39.0, Class II = Lr-0.2/0.23) and demostrated significantly high (>5 SE) T-lymphocyte responses against 10 of 12 strains at 44 dpi. By 72 dpi T-lymphocytes from gilt 3 had significantly high (>5 SE) recognition of all 12 PRRSV isolates and those from gilts 1 and 2 recognized 11 of 12 isolates (Table 1) .
T-lymphocytes from nine 14-day old piglets born to gilt 1 after in utero infection with PRRSV SD23983 were evaluated by IFN-gamma ELISpot assay using the 12 described PRRSV isolates. The infection period totaled 33 days (including 19 days in utero and 14 days after birth) to allow stimulation of PRRSV SD23983 -specifc T-lymphocytes in all piglets. All nine had significant (>5 SE) T-lymphocyte responses against two or more of the heterologous PRRSV isolates tested (Table 2 ). In particular, piglet 13 had T-lymphocytes recognizing all 12 PRRSV isolates including the two type-1 PRRSV isolates. T-lymphocytes from three gilts infected with PRRSV SD23983 at one year of age recognized several epitopes in various viral proteins PRRSV epitopes were initially mapped with high stringency IFN-gamma ELISpot assays using 20 peptide pools (33 to 54 overlapping peptides per pool) spanning all PRRSV SD23983 ORFs. In the first round of epitope mapping, PBMC collected at 30 or 33 dpi had significant T-lymphocyte responses against four to 14 of the 20 peptide pools, depending on the source animal (Table 3 ). This suggested that T-lymphocyte responses to multiple epitopes in several proteins contributed to recognition of diverse PRRSV isolates. In general, the number of peptide pools recognized by T-lymphocytes from the three gilts at 44 or 58 dpi was similar to the findings at 30-33 dpi (Table 3) . Second and third round T-lymphocyte epitope mapping identified a total of 28 peptides recognized by T-lymphocytes from gilt 1 which included four overlapping regions, resulting in mapping of epitopes on !24 peptides ( Table 4) . The viral proteins containing these peptides with epitopes were nsp1 alpha (five peptides, five epitopes), nsp2 (five peptides, !five epitopes), GP2a (two peptides, !two epitopes), GP2b (one peptide, !one epitope), GP4 (six peptides, !five epitopes), GP5 (three peptides, !three epitopes) and M (six peptides, !three epitopes). Gilt 2 T-lymphocytes recognized six peptides including two overlapping regions (!four epitopes) in viral proteins nsp4 (two peptides, !one epitope), GP3 (one peptide, !one epitope), GP4 (one peptide, !one epitope) and M (two peptides, !one epitopes). Gilt 3 T-lymphocytes recognized seven peptides including two overlapping regions (!five epitopes) in viral proteins GP5 (one peptide, !one epitope), M (five peptides, !three epitopes) and N (one peptide, !one epitope). Of these seven peptides, six were also recognized by T-lymphocytes from Neutralizing antibody responses were weak and isolate-specific while Tlymphocytes recognized diverse isolates
To define neutralizing antibody responses, virus neutralizing antibody titers were determined by FFN assay using two type-2 PRRSV, the inoculum PRRSV SD23983 as well as PRRSV VR2332 , which are closely related according to phylogenetic analysis (Fig 1) . All three gilts had weak to moderate neutralizing antibody titers against the homologous PRRSV SD23983 , ranging between 1:4 and 1:32 at 30-72 dpi (Table 5 ). However, there was no detectable level of neutralizing antibodies against the heterologous but closely related PRRSV VR2332 in any of the serum samples from various dpi time points tested (Table 5) . Five of nine piglets had PRRSV-specific T-lymphocyte responses reacting against diverse type 2 PRRSV isolates (!9 of 12 isolates). Of two type-1 isolates, piglet 13 significantly (>5SE) recognized both, while piglets 15 and 21 each recognized one. In contrast, neutralizing antibody responses in all nine piglets were weak against the homologous PRRSV SD23983 isolate Broadly Cross-Reactive T-Lymphocyte Responses in Type-2 PRRSV-Infected Gilts with titers ranging between 1:8 and 1:32, and there was no neutralization of slightly heterologous PRRSV VR2332 (Table 5) . Neutralization results were similar to serum from the dam (gilt 1), with isolate-specific neutralization (Table 5 ). [66] . Studies to date have demonstrated the existence of T-lymphocyte epitopes in several PRRSV proteins including both structural (GP2, GP3, GP5, M, N) and non-structural proteins (nsp1, nsp2, nsp5, nsp7, nsp9 and nsp10) [58] [59] [60] [61] [62] [63] [64] . PRRSV-specific T-lymphocytes in PBMC from infected pigs appeared at 14 dpi and remained longer than 50 days when evaluated in IFN-gamma ELISpot assay using the mixture of PRRSV MN30100 and recombinant N protein as the stimulation antigen [65] . Furthermore, PRRSV-specific T-lymphocyte responses were highly variable between different age groups, potentially related to infection strains and virus titer [66] . To date, no systematic evaluation of the cross-recognition potential of PRRSV-specific T-lymphocyte responses to heterologous PRRSV isolates has been performed. If T-lymphocyte responses recognize multiple epitopes in diverse PRRSV isolates and have a protective function, they may overcome the challenges presented by antigenic variation among PRRSV isolates and weak, isolate-specific neutralizing antibody responses. *Neutralizing antibody titer is the last serum dilution with detectable neutralizing activity.
Discussion
**32 dpi for piglets born to gilt 1 includes 18 days gestation following infection of gilt plus 14 days after birth, at which point the serum sample was obtained.
doi:10.1371/journal.pone.0165450.t005
The objective of this study was to define broadly cross-reactive PRRSV-specific T-lymphocyte responses induced in gilts and piglets after infection with a type-2 PRRSV and map epitope-containing sequence within T-lymphocyte-recognized viral proteins. T-lymphocytes from both age groups recognized multiple diverse PRRSV isolates. In the three 12-month-old gilts, intranasal infection with PRRSV SD23983 induced T-lymphocyte responses that reacted against 10 type-2 isolates and one or both of the two highly divergent type-1 isolates when evaluated by 72 dpi. The recognition of all 12 PRRSV isolates including two type-1 isolates by gilt 3 T-lymphocytes was unexpected considering the antigenic and genetic differences between inoculum PRRSV SD23983 and tested divergent isolates. T-lymphocytes from all nine 14-day-old piglets infected in utero recognized at least two of the 12 PRRSV isolates tested. Importantly, T-lymphocytes from one of the nine piglets recognized all 12 PRRSV isolates and another recognized 11 isolates. This finding could be reinforced through further studies with more diverse PRRSV isolates including high pathogenic strains as well as PBMC at various dpi time points.
The broadly cross-reactive T-lymphocyte responses observed in this study were in direct contrast to the weak and isolate-specific neutralizing antibody responses to the homologous PRRSV SD23983 in gilts when tested at various dpi time points. This strongly supports the effort to define T-lymphocyte responses further with regard to protective mechanisms. Porcine Tlymphocytes that could contribute to protective responses include CD4 + T-lymphocytes, CD8 + T-lymphocytes and memory T-lymphocytes with the double positive CD4 + CD8 + phenotype.
To this end, a companion study using T-lymphocytes from the three gilts in this study demonstrated cytotoxic responses by both CD8 + and CD4 + T-lymphocytes [67] . Additional large scale studies using pigs with systematically defined MHC haplotypes are also indicated to investigate the association between MHC haplotypes and PRRSV-specific IFN-gamma-secreting T-lymphocyte responses, as this limited analysis of gilts and congenitally infected piglets is not definitive. The epitope mapping results in this study identified peptides containing T-lymphocyte epitopes in multiple proteins including nsp4, in which no other T-lymphocyte epitopes have been reported to date. T-lymphocyte epitopes have been previously described in PRRSV nsp1, nsp2, GP2, GP4, GP5, M and N proteins [58] [59] [60] [61] [62] [63] [64] , however in this study the exact locations for 23 of 33 epitope-containing peptides identified in these proteins were novel. Locations of ten peptides including seven M peptides, two GP5 peptides, and one nsp2 peptide were similar to those previously reported. M protein had several epitopes recognized by two of three gilts tested and, in particular, one epitope-containing peptide (P579) that was recognized by T-lymphocytes from all three. It will be interesting to determine if either cytotoxic T-lymphocytes (CTL) and/or helper T-lymphocytes recognize this peptide and whether they potentially recognize the same epitope. In addition, the same repertoire of epitope-containing peptides from the M protein were recognized by two gilts (gilt 1 and gilt 3) with identical MHC class-I and -II haplotypes. Despite differing MHC class-I and -II haplotypes, T-lymphocytes in gilt 1 and 2 recognized a common epitope-containing peptide (P538) in GP4. Identification of M protein sequences recognized by T-lymphocytes in several previous reports [58, 59, 62, 68] as well as in the current study suggest that M protein is epitope-rich region suitable for inducing T-lymphocytes recognizing diverse PRRSV isolates, particularly since PBMCs have originated from genetically diverse pigs infected with various PRRSV genotypes.
Four PRRSV non-structural proteins (nsp5, nsp7, nsp9 and nsp10) reported to contain Tlymphocyte epitopes in previous studies [58, 63, 64] had no epitopes identified in this study. This may have been due to the use of only three gilts for epitope mapping and/or the use of limited dpi time points. Additional studies are planned to undertake epitope mapping and functional analysis of T-lymphocytes through virus suppression and cytotoxic assays using PBMC collected at various dpi from pigs infected with type-1 and type-2 PRRSV strains in order to extend the current findings. In addition, inclusion of high pathogenic PRRSV strains in diverse PRRSV panel as T-lymphocyte stimulation antigen in ELISpot assay may be valuable. Thorough epitope mapping will be crucial in the development of the next generation of PRRSV vaccines, particularly those epitopes that induce CTL and helper T-lymphocytes for both CTL and B-lymphocyte responses. Epitopes recognized by helper T-lymphocytes can be used as an adjuvant for either conventional or novel PRRSV vaccines to boost PRRSV-specific T-or B-lymphocyte responses, and PRRSV-specific CTL epitopes could be included to improve protective vaccine efficacy. 
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